166 related articles for article (PubMed ID: 21906694)
21. Bridging the drug-diagnostic divide.
Opar A
Nat Rev Drug Discov; 2011 May; 10(5):323-4. PubMed ID: 21532548
[No Abstract] [Full Text] [Related]
22. Antibiotics--an investment worth making?
Christoffersen RE
Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
[TBL] [Abstract][Full Text] [Related]
23. Considerations of net present value in policy making regarding diagnostic and therapeutic technologies.
Califf RM; Rasiel EB; Schulman KA
Am Heart J; 2008 Nov; 156(5):879-85. PubMed ID: 19061701
[TBL] [Abstract][Full Text] [Related]
24. Medicines for tropical diseases; support through tax-incentives.
John JE
Drug Discov Today; 2011 Feb; 16(3-4):91-2. PubMed ID: 21111059
[No Abstract] [Full Text] [Related]
25. Unravel the mysteries of DM return-on-investment.
Healthc Demand Dis Manag; 1999 Sep; 5(9):129-34. PubMed ID: 10621123
[No Abstract] [Full Text] [Related]
26. Deal watch: Trends in discovery externalization.
Mayhew S
Nat Rev Drug Discov; 2010 Mar; 9(3):183. PubMed ID: 20190781
[No Abstract] [Full Text] [Related]
27. Any diamonds in the diagnostic coal?
Jacobs T
Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
[No Abstract] [Full Text] [Related]
28. No pain, no gain?
Jacobs T
Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
[No Abstract] [Full Text] [Related]
29. Japanese firms broaden investment focus to early biotech.
Louët S; Sipp D
Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
[No Abstract] [Full Text] [Related]
30. Realizing positive returns from your e-health investments.
O'Dell S; McGoldrick C
Healthc Financ Manage; 2001 Feb; 55(2):50-5. PubMed ID: 11271443
[TBL] [Abstract][Full Text] [Related]
31. Your money or your life.
Westphal SP
New Sci; 2002 Jul; 175(2351):28-33. PubMed ID: 12625339
[No Abstract] [Full Text] [Related]
32. A pilot study to document the return on investment for implementing an ambulatory electronic health record at an academic medical center.
Grieger DL; Cohen SH; Krusch DA
J Am Coll Surg; 2007 Jul; 205(1):89-96. PubMed ID: 17617337
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers: refining diagnosis and expediting drug development - reality, aspiration and the role of open innovation.
Salter H; Holland R
J Intern Med; 2014 Sep; 276(3):215-28. PubMed ID: 24605903
[TBL] [Abstract][Full Text] [Related]
34. Rewarding innovation in drug discovery.
Lopes G
Health Aff (Millwood); 2009; 28(3):922-3. PubMed ID: 19414906
[No Abstract] [Full Text] [Related]
35. Roche chases stake in medical sequencing.
Hayden EC
Nature; 2012 Apr; 484(7393):152. PubMed ID: 22498604
[No Abstract] [Full Text] [Related]
36. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
Chackalamannil S; Desai MC
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640
[TBL] [Abstract][Full Text] [Related]
37. Competitive collaboration in the pharmaceutical and biotechnology industry.
Bingham A; Ekins S
Drug Discov Today; 2009 Dec; 14(23-24):1079-81. PubMed ID: 19835979
[No Abstract] [Full Text] [Related]
38. The decline and fall of the psychopharmacology empire?
Norman TR
Aust N Z J Psychiatry; 2011 Nov; 45(11):1005. PubMed ID: 21985246
[No Abstract] [Full Text] [Related]
39. The gold industry standard for risk and cost of drug and vaccine development revisited.
Pronker ES; Weenen TC; Commandeur HR; Osterhaus AD; Claassen HJ
Vaccine; 2011 Aug; 29(35):5846-9. PubMed ID: 21722688
[TBL] [Abstract][Full Text] [Related]
40. Adoption agent.
Peota C
Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
